

Plasma homocysteine response to folic acid intervention

Submission date 29/01/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 05/03/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 02/02/2011	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mary Ward

Contact details
Northern Ireland Centre for Food and Health
School of Biomedical Sciences
University of Ulster
Coleraine
United Kingdom
BT521SA
+44 (0)28 7032 3076
mw.ward@ulster.ac.uk

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
A dose finding trial in ischaemic heart disease patients and healthy controls to determine whether chronic exposure to low-dose folic acid can lower homocysteine

Study objectives

Low dose folic acid (0.2 mg/d) administered chronically will significantly lower plasma homocysteine in ischaemic heart disease (IHD) patients and healthy age-sex matched controls. Previous studies may have overestimated the folic acid dose required to lower homocysteine because of too-short an intervention period to observe the full extent of the response to low folic acid doses and concluded that much higher doses were required for maximal homocysteine-lowering.

If the hypothesis is confirmed the findings will have important implications for governments worldwide currently considering food fortification with folic acid, which although primarily aimed at reducing neural tube defects (NTDs), is expected to have important benefits in terms of the primary and secondary prevention of cardiovascular disease (CVD) via a homocysteine-lowering effect.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by the University of Ulster Ethics committee in March 2000 (ref: 01/17).

Study design

Double-blinded, randomised, placebo controlled dose finding trial with folic acid

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Ischaemic heart disease

Interventions

In both IHD and healthy control groups, participants were stratified into tertiles of homocysteine concentration (from the screening blood sample). Subjects in each stratum were then randomised to receive placebo, 0.2, 0.4 or 0.8 mg/d folic acid for a total intervention period of 26 weeks. To maximise compliance, vitamins were distributed every three weeks to the participants homes in seven-day pillboxes. The pillboxes were then collected and any unused pills recorded in order to monitor compliance.

Total intervention period of 26 weeks for all treatment arms.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Folic acid

Primary outcome(s)

Plasma homocysteine, measured at baseline, 6 weeks and 12 weeks in a subset, and at 26 weeks.

Key secondary outcome(s)

1. Serum folate, measured at baseline and at 26 weeks
2. Erythrocyte glutathione reductase activity coefficient (EGRac): an indicator of riboflavin status), measured at baseline
2. Plasma pyridoxal phosphate: an indicator of vitamin B6 status, measured at baseline
3. Serum vitamin B12, measured at baseline

Completion date

31/12/2004

Eligibility**Key inclusion criteria**

1. Male and female, any age
2. IHD Patients:
 - 2.1. Proven myocardial infarction more than three months previously
 - 2.2. IHD on coronary angiography
 - 2.3. A clinical diagnosis of angina confirmed by electrocardiogram (ECG)
3. Control subjects: healthy subjects age- and sex-matched with the IHD group from the local community

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. IHD patients:
 - 1.1. History of diabetes
 - 1.2. Hepatic or renal disease
 - 1.3. Haematological disorders
 - 1.4. Use of B-vitamin supplements or use of medication known to interfere with folate metabolism
2. Healthy controls in addition had no history of CVD

Date of first enrolment

31/03/2001

Date of final enrolment

31/12/2004

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Northern Ireland Centre for Food and Health

Coleraine

United Kingdom

BT521SA

Sponsor information

Organisation

University of Ulster (UK)

ROR

<https://ror.org/01yp9g959>

Funder(s)

Funder type

Charity

Funder Name

Northern Ireland Chest Heart and Stroke Association (UK)

Alternative Name(s)

NICHHS

Funding Body Type

Private sector organisation

Funding Body Subtype

Associations and societies (private and public)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2011		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes